Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment
of a variety of malignant and autoimmune disorders. Despite this success, a substantial …

The anti-CD20 mAb rituximab has substantially improved the clinical outcome of patients with
a wide range of B-cell malignancies. However, many patients relapse or fail to respond to …

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given
in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-…

The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance
remains a significant problem. We recently reported that resistance could be explained, in …

Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes
due to compromised immune responses, but the insights of these studies have been …

Individuals with lymphoid malignancies are at risk of developing severe COVID-19 and are
less likely to develop protective immune responses to SARS-CoV-2 vaccination than the …

Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid
cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here, …

A major feature that distinguishes type I from type II anti-CD20 monoclonal antibodies (mAbs)
and reduces their therapeutic efficacy is the tendency to internalize from the cell surface. …

Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour
efficacy in multiple preclinical models but modest clinical responses. This might reflect current …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and
infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease …